[Ovid] Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007)

lisa_lisa Post time 2024-3-28 10:19:13 | Show all posts |Read mode

Reward10points

journal：Neurology

Authors：Tahseen Mozaffar; Benedikt Schoser; Priya Kishnani; Drago Bratkovic; Paula R. Clemens; Ozlem Goker-Alpan; Xue Ming; Mark Roberts; Kumaraswamy Sivakumar; Ans Van Der Ploeg; Mitchell Goldman; Jacquelyn Wright; Fred Holdbrook; Vipul Jain; Sheela Sitaraman; Yasmine Wasfi; Barry Byrne

Published date：2023-4-25

DOI：10.1212/wnl.0000000000202282

PDF link：https://syndication.highwire.org ... NL.0000000000202282

Article link：http://dx.doi.org/10.1212/wnl.0000000000202282

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

lisa_lisa Lv.2

Junior Member

post
reply
points
50

[Ovid] Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007)

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Ovid] Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007) Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Ovid] Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007)